Drug Type Antibody drug conjugate (ADC) |
Synonyms SIM 0686, SIM0686 |
Target |
Action inhibitors |
Mechanism FGFR2b inhibitors(fibroblast growth factor receptor 2 IIIb inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| FGFR2 Mutation Solid Tumors | Phase 1 | China | 06 May 2025 | |
| Solid tumor by Site | Phase 1 | China | 06 May 2025 | |
| FGFR2 Mutant Neoplasms | IND Approval | United States | 21 Jul 2025 |






